Tech Company Financing Transactions
Elegen Funding Round
On 5/15/2024, Elegen announced $35 million in Series B funding from Triatomic Capital, 8VC and ACVC Partners.
Transaction Overview
Company Name
Announced On
5/15/2024
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
Triatomic Capital (Lead Investor) (Peter Zhou)
private investors (John Ballantyne)
Proceeds Purpose
The company intends to use the funds to accelerate the extension of its ENFINIA� DNA product line across clinical workflows providing the production of GMP-compliant DNA for clinical development of genetic medicines.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1300 Industrial Road 16
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Undisclosed
Website
Email Address
Overview
The growing bioeconomy will demand synthetic biology performed on a scale not possible without innovation of the DNA manufacturing process. Elegen will help the builders in the next evolution of synthetic biology eliminate expensive, time and capital-intensive workflows by using innovative methods and technologies to provide fast-turnaround, high-accuracy, complex, long, synthetic DNA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matt Hill
Chief Financial Officer
Jodie Bowen
Chief Scientific Officer
Marc Unger
VP - Bus. Development
Dan La Caze
VP - Bus. Development
Kevin Louder
VP - R & D
Steven Lin
Browse more venture capital transactions:
Prev: 5/15/2024: Enspired venture capital transaction
Next: 5/15/2024: Harbor Lab venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs